Is BRCTF or XYLD a better dividend investment in 2026?

BRCTF currently yields 6.06% with a 5% 5-year dividend growth rate. XYLD yields 11.20% with 0.5% growth. The better choice depends on your goal: XYLD offers higher current income.

What is the dividend yield difference between BRCTF and XYLD?

BRCTF has a forward dividend yield of 6.06% ($2.00/share annually). XYLD yields 11.20% ($4.30/share annually). The yield gap is 5.14 percentage points.

Home › Compare › BRCTF vs XYLD

BRCTF vs XYLD: Dividend Comparison 2026

BRCTF yields 6.06% · XYLD yields 11.20%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BRCTF wins by $4.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

BRCTF

● Live price

6.06%

Share price

$33.02

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.8K

Annual income

$891.01

Full BRCTF calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

11.20%

Share price

$38.36

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.9K

Annual income

$3,351.03

Full XYLD calculator →

Portfolio growth — BRCTF vs XYLD

📍 BRCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BRCTF	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BRCTF + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BRCTF pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRCTF

Annual income on $10K today (after 15% tax)

$514.84/yr

After 10yr DRIP, annual income (after tax)

$757.36/yr

XYLD

Annual income on $10K today (after 15% tax)

$952.37/yr

After 10yr DRIP, annual income (after tax)

$2,848.38/yr

At 15% tax rate, XYLD beats the other by $2,091.02/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRCTF + XYLD for your $10,000?

BRCTF: 50%XYLD: 50%

100% XYLD50/50100% BRCTF

Portfolio after 10yr

$27.8K

Annual income

$2,121.01/yr

Blended yield

7.62%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRCTF buys

XYLD buys

No recent congressional trades found for BRCTF or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBRCTFXYLD

Forward yield	6.06%	11.20% ✓
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$29.8K ✓	$25.9K
Annual income after 10y	$891.01	$3,351.03 ✓
Total dividends collected	$7.5K	$20.2K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: BRCTF vs XYLD ($10,000, DRIP)

Year	BRCTF Portfolio	BRCTF Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$11,306	$605.69	$10,840	$1,120.44	+$466.00 → BRCTF
2	$12,737	$639.98	$11,786	$1,249.59	+$951.00 → BRCTF
3	$14,303	$673.84	$12,854	$1,397.78	+$1.4K → BRCTF
4	$16,011	$707.15	$14,063	$1,568.33	+$1.9K → BRCTF
5	$17,871	$739.83	$15,434	$1,765.19	+$2.4K → BRCTF
6	$19,894	$771.78	$16,995	$1,993.14	+$2.9K → BRCTF
7	$22,090	$802.93	$18,777	$2,257.95	+$3.3K → BRCTF
8	$24,469	$833.21	$20,818	$2,566.58	+$3.7K → BRCTF
9	$27,045	$862.59	$23,163	$2,927.50	+$3.9K → BRCTF
10	$29,829	$891.01	$25,865	$3,351.03	+$4.0K → BRCTF

BRCTF vs XYLD: Complete Analysis 2026

BRCTF — Stock

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.

Full BRCTF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this BRCTF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRCTF vs SCHD BRCTF vs JEPI BRCTF vs O BRCTF vs KO BRCTF vs MAIN BRCTF vs QYLD BRCTF vs JEPQ BRCTF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.